(4-Cyanphenyl)diphenylmethanol | 57808-43-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (4-Cyanphenyl)diphenylmethanol
• 英文别名: Diphenyl-(p-cyanophenyl)carbinol；4-(hydroxy(diphenyl)methyl)benzonitrile；4-[Hydroxy(diphenyl)methyl]benzonitrile
• CAS: 57808-43-2
• 化学式: C₂₀H₁₅NO
• 分子量: 285.345
• InChiKey: HLEBLTLDIXQPRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-Cyanphenyl)diphenylmethanol 在 lithium aluminium tetrahydride 、 三氟乙酸 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 N-(4-(((2-aminoethyl)sulfanyl)(diphenyl)methyl)benzyl)acetamide
  参考文献：
  名称：

  Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity

  摘要：

  The human mitotic kinesin Eg5 represents a novel mitotic spindle target for cancer chemotherapy. We previously identified S-trityl-L-cysteine (STLC) and related analogues as selective potent inhibitors of Eg5. We herein report on the development of a series of 4,4,4-triphenylbutan-1-amine inhibitors derived from the STLC scaffold. This new generation systematically improves on potency: the most potent C-trityl analogues exhibit K-i(aPP) <= 10 nM and GI(50) approximate to 50 nM, comparable to results from the phase II clinical benchmark ispinesib. Crystallographic studies reveal that they adopt the same overall binding configuration as S-trityl analogues at an allosteric site formed by loop L5 of Eg5. Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition. One triphenylbutanamine analogue and ispinesib possess very good bioavailability (51% and 45%, respectively), with the former showing in vivo antitumor growth activity in nude mice xenograft studies.

  DOI：

  10.1021/jm201195m
• 作为产物：
  描述：

  二苯甲酮 、 4-溴苯腈 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 28.5h， 以68%的产率得到(4-Cyanphenyl)diphenylmethanol
  参考文献：
  名称：

  Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity

  摘要：

  The human mitotic kinesin Eg5 represents a novel mitotic spindle target for cancer chemotherapy. We previously identified S-trityl-L-cysteine (STLC) and related analogues as selective potent inhibitors of Eg5. We herein report on the development of a series of 4,4,4-triphenylbutan-1-amine inhibitors derived from the STLC scaffold. This new generation systematically improves on potency: the most potent C-trityl analogues exhibit K-i(aPP) <= 10 nM and GI(50) approximate to 50 nM, comparable to results from the phase II clinical benchmark ispinesib. Crystallographic studies reveal that they adopt the same overall binding configuration as S-trityl analogues at an allosteric site formed by loop L5 of Eg5. Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition. One triphenylbutanamine analogue and ispinesib possess very good bioavailability (51% and 45%, respectively), with the former showing in vivo antitumor growth activity in nude mice xenograft studies.

  DOI：

  10.1021/jm201195m

文献信息

• [EN] DUTPASE INHIBITORS<br/>[FR] INHIBITEURS DE DUTPASE
  申请人：MEDIVIR AB

  公开号：WO2005065689A1

  公开（公告）日：2005-07-21

  Deoxyuridine derivatives of the formula (I) where R1 is H or various substituents; D is -NHCO-, -CONH-, -0-, -C(=O)-, -CH=CH, -CΞC-, -NR5-; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or a stable monocyclic, bicyclic or tricyclic ring system; G is -O-, -S-, -CHR10-, -C(=O)-; J is -CH2-, or when G is CHR10 may also be -O- or -NH-; R10 is H, F, -CH3, -CH2NH2, -CH2OH; -OH R11 is H, F, -CH3, -CH2 NH2, -CH2OH, CH(OH)CH3, CH(NH3)CH3; or R10 and R11 together define an olefinic bond, or together form a -CH2-group, thereby defining a cis or trans cyclopropyl group; have utility in the prophylaxis or treatment of protozoal diseases such as malaria.

  脱氧尿嘧啶衍生物的公式(I)，其中R1是H或不同的取代基；D是-NHCO-，-CONH-，-0-，-C(=O)-，-CH=CH，-CΞC-，-NR5-；R4是氢或不同的取代基；R5是H，C1-C4烷基，C1-C4烷酰基；E是Si或C；R6、R7和R8独立地选自C1-C8烷基，C2-C8烯基，C2-C8炔基或稳定的单环、双环或三环环系；G是-O-，-S-，-CHR10-，-C(=O)-；J是-CH2-，或者当G是CHR10时，也可以是-O-或-NH-；R10是H，F，-CH3，-CH2NH2，-CH2OH；-OH R11是H，F，-CH3，-CH2 NH2，-CH2OH，CH(OH)CH3，CH(NH3)CH3；或者R10和R11共同定义一个烯丙基键，或者共同形成一个-CH2-基团，从而定义一个顺式或反式环丙基基团；在预防或治疗疟疾等原虫性疾病方面具有用途。
• A MILD REDUCTION OF BENZYL ALCOHOLS WITH DIPHOSPHORUS TETRAIODIDE
  作者：Hitomi Suzuki、Hiroyuki Tani、Hirohisa Kubota、Naofumi Sato、Junko Tsuji、Atsuhiro Osuka

  DOI：10.1246/cl.1983.247

  日期：1983.2.5

  On treatment with diphosphorus tetraiodide in boiling benzene, benzyl alcohols are smoothly reduced to parent hydrocarbons in good to moderate yields.

  在沸腾的苯中用四碘二磷处理时，苄醇可以顺利地还原为相应的母体烃，产率良好至中等。
• Dutpase Inhibitors
  申请人：Gilbert Ian

  公开号：US20080300216A1

  公开（公告）日：2008-12-04

  Deoxyuridine derivatives of Formula (I′); where A is O, S or CH 2 ; B is O, S or CHR 3 ; R 1 is H, or various substituents; R 2 is H, F; R 3 is H, F, OH, NH 2 ; or R 2 and R 3 together form a chemical bond; D is —NHCO—, —CONH—, —O—, —C(═O)—, —CH═CH, —C≡C—, —NR 5 —; R 4 is hydrogen or various substituents; R 5 is H, C 1 -C 4 alkyl, C 1 -C 4 alkanoyl; E is Si or C; R 6 , R 7 and R 8 are independently selected from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system have utility in the prophylaxis of treatment of parasitic diseases such as malaria.

  化合物（I'）的脱氧尿嘧啶衍生物；其中A为O、S或CH2；B为O、S或CHR3；R1为H或各种取代基；R2为H、F；R3为H、F、OH、NH2；或R2和R3共同形成化学键；D为-NHCO-、-CONH-、-O-、-C（═O）-、-CH═CH、-C≡C-、-NR5-；R4为氢或各种取代基；R5为H、C1-C4烷基、C1-C4酰基；E为Si或C；R6、R7和R8分别选择自C1-C8烷基、C2-C8烯基、C2-C8炔基或稳定的单环、双环或三环环系统，在预防或治疗疟疾等寄生虫病方面具有用途。
• DUTPASE INHIBITORS
  申请人：Gilbert Ian

  公开号：US20100075924A1

  公开（公告）日：2010-03-25

  Deoxyuridine derivatives of the formula where A is O, S or CH 2 ; B is O, S or CHR 3 ; R 1 is H, or various substituents; R 2 is H, F; R 3 is H, F, OH, NH 2 ; or R 2 and R 3 together form a chemical bond; D is —NHCO—, —CONH—, —O—, —C(═O)—, —CH═CH, —C ═ C—, —NR 5 —; R 4 is hydrogen or various substituents; R 5 is H, C 1 -C 4 alkyl, C 1 -C 4 alkanoyl; E is Si or C; R 6 , R 7 and R 8 are independently selected from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system have utility in the prophylaxis o treatment of parasitic diseases such as malaria

  Deoxyuridine衍生物的公式为： 其中A为O、S或CH2；B为O、S或CHR3；R1为H或各种取代基；R2为H、F；R3为H、F、OH、NH2；或R2和R3共同形成化学键；D为—NHCO—、—CONH—、—O—、—C(═O)—、—CH═CH、—C═C—、—NR5—；R4为氢或各种取代基；R5为H、C1-C4烷基、C1-C4酰基；E为Si或C；R6、R7和R8分别选自C1-C8烷基、C2-C8烯基、C2-C8炔基或稳定的单环、双环或三环环系统。 具有预防或治疗疟疾等寄生虫病的功效。
• Preparation of isobutene homo- or copolymer derivatives
  申请人：BASF SE

  公开号：US10745496B2

  公开（公告）日：2020-08-18

  A process for preparing isobutene homo- or copolymer derivatives by (i) polymerizing isobutene or an isobutene-comprising monomer mixture in the presence of an iron halide-donor complex, an aluminum trihalide-donor complex, or an alkylaluminum halide-donor complex, (ii) reacting a resulting high-reactivity isobutene polymer with a compound which introduces a low molecular weight polar group or a substructure thereof, and (iii) in the case of reaction with a substructure, further reacting to complete the formation of the low molecular weight polar group. The homo- or copolymer derivatives include a radical of a hydrophobic polyisobutene polymer having a number-average molecular weight of 110 to 250 000 and low molecular weight polar groups including amino functions, nitro groups, hydroxyl groups, mercaptan groups, carboxylic acid or carboxylic acid derivative functions, sulfonic acid or sulfonic acid derivative functions, aldehyde functions and/or silyl groups.

  一种制备异丁烯均聚物或共聚物衍生物的工艺，其方法是 (i) 在卤化铁络合物、三卤化铝络合物或烷基卤化铝络合物存在下，使异丁烯或含有异丁烯的单体混合物聚合、(iii) 在与亚结构反应的情况下，进一步反应以完成低分子量极性基团的形成。均聚物或共聚物衍生物包括疏水性聚异丁烯聚合物的基团，其平均分子量为 110 至 250 000，低分子量极性基团包括氨基、硝基、羟基、硫醇基、羧酸或羧酸衍生物、磺酸或磺酸衍生物、醛基和/或硅基。